SUMMARY Serum from patients with rheumatoid arthritis (RA) receiving disodium aurothiomalate was analysed for total gold by atomic absorption spectrometry and for unbound (free) gold by the same method after ultrafiltration by an inert membrane. It was shown that it is possible to obtain reliable free gold concentrations by this method. Good correlations were shown between total and 'free' gold and between total and protein bound gold (PBG) for 54 patients with RA who were stabilised on gold therapy. Significant correlation was also shown between the same parameters for a second group of 15 patients starting gold therapy who were bled at weekly intervals for nine weeks immediately before medication. A single correlation with regression for all patients studied again showed good correlation between total and free gold and between total and PBG. Of the 189 paired values plotted, 182 fell within 2SD of the regression lines for the two plots. Of the seven patients with results outside 2SD of the regression line, six presented with side effects during the study.
ment.
It has been shown that most of the gold given to patients suffering from rheumatoid arthritis (RA) as aurothiomalate is present in the serum bound to albumin and to a lesser extent bound to the remaining protein fractions. -8 It has also been established that with several drugs the unbound rather than the total or protein bound concentration shows a better correlation with pharmacological response.9-1" In consequence it has been suggested that unbound (or free) serum gold might be a useful parameter for monitoring patients during chrysotherapy.7 12 Until recently methods of assaying free serum gold have either been unsuccessful or between total gold and free gold (r=0.80, p=0005, n=54, where p is the measure for the significance of the results and n is the number of paired results observed) and between total gold and PBG (r=0.99, p=00055 n=54).
Good correlation was also obtained in group 2 patients between total gold and free gold (r=0.79, p=O005, n=135) and between total gold and PBG (r=0-99, p=0005, n=135).
The single correlation with regression for results from all patients in the two study groups (i.e., the initial established group of 54 plus the nine serial analyses for the 15 patients starting therapy) again showed significant correlation both between total and free gold (r=0.75, p=0*005, n=189) and between total and PBG (r=0.99, p=0*005, n=189). When limits of 2SD were added to the plots of the regression lines it was observed that in each case 182 of the 189 plots were within the limits set and seven fell outside the limits (see Figs 1 and 2 ).
Discussion
When ultrafiltration cones were used analyses were carried out rapidly and with good precision. The results obtained from the precision study show that good reproducibility is possible for free gold in serum using this technique.
Levels of free gold were detected which were up to 12% of the total serum gold levels measured. This is in agreement with the work done by Campion et al.2' The analyses for free gold were performed up to one week after the blood samples were obtained by venous section. The results obtained differ from the studies made by Danpure, 22 who was unable to detect the free gold moiety from 100 minutes onwards after gold injection.
It is evident from the results that there is good correlation between serum total gold and free gold and between total gold and PBG for patients starting gold therapy and for those stabilised on therapy. Furthermore, the single correlation with regression for the combined results from the two groups of patients for total against free gold and total against PBG showed that in all but seven cases the correlation points were within 2SD of the regression lines (see Figs 1 and 2) .
Retrospective analysis of patients' notes showed that of these seven patients, five had developed rashes at the time of study and one had transient thrombocytopenia. Data on the seventh patient were not available. No other patient in either group developed side effects over the study period. It is possible that toxicity may be related to a higher free to total serum gold ratio and also to a lower PBG to total gold ratio.
A study is now in progress in which blood is taken from patients receiving gold therapy for RA who present with toxic reactions and then again after the disappearance of the reaction when treatment is temporarily withheld. Blood is analysed for total, free, and protein bound gold and the results entered on the regression plots. In this way it may be possible to show any relation existing between the toxicity of gold treatment and the distribution of gold in the serum.
Patients showing side effects in this study represent 11% of all patients studied as opposed to the more usual figure of 25 to 33%. There are several possible explanations for this low incidence of toxic reactions in the patient population studied: (a) The initial group of 54 subjects was selected on the basis that they were stabilised on therapy and might therefore be expected to have a lower incidence of toxic reactions. (b) The average weekly gold dose for each patient in the study was 20 mg as opposed to the more usual 50 mg/week. This regimen is used at this hospital because of the apparently lower rates of toxicity. (c) The 15 patients studied in group 2 were followed up for nine weeks after starting therapy. As the usual figure of 25 to 33% for patients showing side effects is normally applied to subjects studied during 12 
